Publications by authors named "Peter Morcos"

Claim this Profile
N
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.
Ashley L Lennox, Fei Huang, Mario González-Sales, Ying Wan, Libo Sun, Peter N Morcos

Clin Transl Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput alloy and process design for metal additive manufacturing.
Sofia Sheikh, Brent Vela, Pejman Honarmandi, Peter Morcos, David Shoukr

NPJ Comput Mater· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.
Benedito A Carneiro, Robert M Jotte, Nashat Y Gabrail, Kristopher Wentzel, Funan Huang, Peter N Morcos

Cancer Res Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.
Ashley L Lennox, Libo Sun, Fei Huang, Melissa Kelly Behrs, Robert Kleiman, Peter N Morcos

Clin Transl Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.
Ashley L Lennox, Fei Huang, Melissa Kelly Behrs, Mario González-Sales, Neha Bhise, Peter N Morcos

Clin Transl Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
Pier Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Peter N Morcos

Blood Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
Mario González-Sales, Ashley L Lennox, Fei Huang, Chandra Pamulapati, Ying Wan, Peter N Morcos

CPT Pharmacometrics Syst Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Peter N Morcos, Jonathan Moss, Josh Veasy, Florian Hiemeyer, Barrett H Childs

Clin Pharmacol Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Peter N Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani

CPT Pharmacometrics Syst Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
Peter N Morcos, Jan Schlender, Rolf Burghaus, Jonathan Moss, Adam Lloyd

Clin Transl Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Rafal Dziadziuszko, Solange Peters, Tony Mok, D Ross Camidge, Shirish M Gadgeel, Peter N Morcos

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Peter N Morcos

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Joy C Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N Morcos

CPT Pharmacometrics Syst Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz C Offner, Peter N Morcos

J Clin Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities.
Peter N Morcos, Junyi Li, Iraj Hosseini, Chi-Chung Li

Clin Transl Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
Wenying Angela Liu, Li Yu, Peter N Morcos, Francois Mercier, Barbara J Brennan

Cancer Chemother Pharmacol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
Sai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, James Chih-Hsin Yang, Luigi De Petris, Peter N Morcos

Lung Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab dosing in hematological malignancies: an old question, revisited.
Peter N Morcos, Axel Boehnke, Nancy Valente, Donald E Mager

Cancer Chemother Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Christina Claus, Claudia Ferrara, Wei Xu, Johannes Sam, Sabine Lang, Peter N Morcos

Sci Transl Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Peter N Morcos

Lancet Respir Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Peter N Morcos, Jiang Liu, Gideon M Blumenthal, Hong Zhao

Clin Pharmacol Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Peter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, Elena Guerini, Markus Abt

J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Yumi Cleary, Michael Gertz, Peter N Morcos, Li Yu, Kuresh Youdim

Clin Pharmacol Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu

Cancer Chemother Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolites of alectinib in human: their identification and pharmacological activity.
Mika Sato-Nakai, Kosuke Kawashima, Toshito Nakagawa, Yukako Tachibana, Miyuki Yoshida, Peter N Morcos

Heliyon· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis